Dr. Björklund is Partner of Tellacq AB, a private investment firm. He joined the BONESUPPORT Board in December 2016 in conjunction with the Company’s $37 million (SEK 315 million) financing, which was led by Tellacq. Dr. Björklund has a long and successful track record in the healthcare industry, including as the former CEO of Nycomed, which he grew from a small Scandinavian company into a global business before its acquisition by Takeda in 2011. He is currently chairman of the board of Swedish Orphan Biovitrum AB and an Industry Executive at Avista Capital Partners. He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.
Holdings in BONESUPPORT: Håkan Björklund owns 25 percent of Tellacq AB that holds 2,264,151 shares and 4,900,000 warrants in BONESUPPORT. Independent in relation to the Company and its management and in relation to major shareholders.
M.D, Ph.D, Professor in Orthopaedics at the University Hospital of Lund
Dr. Lidgren is leading a regenerative medicine research group at the university department in Lund, which is a member of the ISOC group of worldwide leading hospitals. He is an honorary member of and served as president of several major societies, and initiated the worldwide Bone and Joint Decade 2000-2010. Dr. Lidgren is a successful serial entrepreneur who founded the companies Scandimed (Biomet), AMeC and GWS, Sweden. He is also a board member of the stock listed companies Orthocell, Australia and GWS, Sweden.
Holdings in BONESUPPORT: 492,926 shares and 860,985 employee stock options. Independent in relation to the Company and its management and in relation to major shareholders.
M.D, Ph.D, Karolinska Institute in Stockholm
A founding partner of HealthCap. Dr. Odlander is a Medical Doctor and was previously a member of ABB Aros Management Committee and headed the Aros Health Care Team. Prior to joining Aros in 1992, Dr. Odlander was active at the Karolinska Institute, Stockholm, Sweden. In addition to teaching medical students, he pursued scientific research in the biochemistry of inflammation. Dr. Odlander serves on the boards of the following comapanies; among others: Cardoz AB, OxThera AB, LTB4 Sweden AB and Nordic Nanovector AS.
Holdings in BONESUPPORT: None. Independent in relation to the Company and its management, but not in relation to major shareholders. Partner in HealthCap and board member in several companies in the HealthCap group.
Previously, Dr. Rawal held the position of Vice President, Ventures at Gambro. Prior experience also includes The Boston Consulting Group in Stockholm and New York, Swecare foundation, and a Ph.D in molecular neurobiology at the Karolinska Institute in Stockholm and Hôpital la Salpêtrière in Paris. Dr. Rawal serves on the boards of Smartfish, Airsonett and Glionova, and on a pro bono basis, as advisor to Médecins Sans Frontières. She holds an MSc in Biomedicine from the Karolinska Institute.
Holdings in BONESUPPORT: None. Independent in relation to the Company and its management, but not in relation to major shareholders. Employed by Stiftelsen Industrifonden.
Tone Kvåle has more than 20 years of experience gained in the biotech industry. She has been Chief Financial Officer at Nordic Nanovector ASA since November 2012. Prior to joining Nordic Nanovector, she was CFO of NorDiag, Kavli Holding and Dynal Biotech, and has held senior management positions at Invitrogen, Life Technologies and ThermoFisher (US). Ms. Kvåle has a diploma in Finance & Administration from Harstad University College.
Holdings in BONESUPPORT: None. Independent in relation to the Company and its management and in relation to major shareholders.
Senior Advisor at Patricia Industries AB since 2015, Lennart was previously Managing Director (Business Development, Operating and Financial Investments) at Investor AB (2006-2015). Prior to this he was Partner and Chief Executive Officer of Emerging Technologies ET AB. He is currently Board Member of Swedish Orphan Biovitrum AB and Hi3G Access AB; Deputy Chairman of Mölnlycke Health Care AB; and Chairman of Vectura AB. Lennart holds an MBA from the Stockholm School of Economics (1980).
Holdings in BONESUPPORT: 30,000 shares. Independent in relation to the Company and its management and in relation to major shareholders.